Normal view MARC view ISBD view

Early mortality benefit with COVID-19 convalescent plasma: a matched control study.

MedStar author(s):

0007-1048

Name of journal: British journal of haematologyAbstract: Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25.5%) compared to controls (27%, P = 0.06). Seven-day mortality was statistically better for CCP cases (9.1%) than controls (19.8%, P < 0.001) and continued at 14 days (14.8% vs. 23.6%, P = 0.01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0.02). The length of stay was longer in CCP cases than controls (14.3 days vs. 11.4 days, P < 0.001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls. Copyright (c) 2020 British Society for Haematology and John Wiley & Sons Ltd.All authors: Baez V, Blumenthal J, Fernandez SJ, Hettinger AZ, Shenoy AGOriginally published: British Journal of Haematology. 2021 Jan 22Fiscal year: FY2021Digital Object Identifier:

https://dx.doi.org/10.1111/bjh.17272

ORCID:

https://orcid.org/0000-0002-5018-8967

Date added to catalog: 2021-02-17

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	33482025	Available		33482025

Available online through MWHC library: 1995 - 2013

Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25.5%) compared to controls (27%, P = 0.06). Seven-day mortality was statistically better for CCP cases (9.1%) than controls (19.8%, P < 0.001) and continued at 14 days (14.8% vs. 23.6%, P = 0.01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0.02). The length of stay was longer in CCP cases than controls (14.3 days vs. 11.4 days, P < 0.001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls. Copyright (c) 2020 British Society for Haematology and John Wiley & Sons Ltd.

English